Global Malaria Burden

  • 228,000,000 cases of malaria annually

  • 405,000 deaths per year​​​​


 - World Health Organization (WHO)

Current Diagnostics

  • Current gold standard testing, including rapid diagnostic tests and microscopy, can miss malaria cases.

  • This is particularly a problem in patients that have low levels of malaria parasite at the time of the test or when diagnosing pregnant women.​

  • Patients that have been misdiagnosed, or do not show symptoms act as a reservoir for future malaria transmission.

  • Current ultra-sensitive diagnostics on the market are not designed to be robust enough for deployment in rural Africa and other malaria-endemic regions.

The Illucidx Malaria Dx Solution

Illucidx team members from the University of Calgary have collaborated with partners in Ethiopia to advance malaria diagnostics for years.

  • We have seen firsthand what is feasible and what is not when deploying diagnostics in remote malaria-endemic regions of the world.

  • The solution we are developing is 100 to 1000 times more sensitive than the current field-deployed diagnostics.

  • It is specifically designed to be robust and simple to use with minimal training and laboratory infrastructure; dedicated laboratory space and consistent electricity will not be required.

  • Our test is shelf-stable, allowing it to be brought to point-of-care with detection levels comparable to those of laboratory-based tests.

  • Cost that is economical and practical for large scale deployment in low and middle-income countries.

  • We are currently perfecting moving our diagnostic chemistry to a cartridge-based system.


Headquartered in Calgary, Alberta, Canada we hope to enable broad access to ultra-sensitive diagnostics tools for settings across the globe. Our first priority is, and will always remain, to improve clinical outcomes.

Please email for direct number


3655 36 St NW 

Calgary, AB T2L 1Y8


  • LinkedIn

© 2020 Illucidx Inc Previously Elucidx Inc.